Skip to main content
All Posts By

admin

475th Edition, September 29, 2021

By BHI Weekly Newsletter Archives





Trouble Viewing This Email: Click Here

September 29, 2021

FOUNDING MEMBER OF

Summary Graphic

BIOTtalk: From the 7th Annual BioHealth Capital Region Forum – Dr. Tara Schwetz, Assistant Director for Biomedical Science Initiatives, White House Office of Science and Technology Policy (OSTP)

Listen now via Google https://bit.ly/3EWtTtJ, Apple https://apple.co/3ocpP2w, Spotify https://spoti.fi/3EUALYu, and TuneIn https://bit.ly/3CGZ8Ho.

The session from the BioHealth Capital Region Forum focuses on a vision for a new science entity, the Advanced Research Projects Agency for Health (ARPA-H). This new NIH Institute would accelerate biomedical innovation and adoption of technologies and approaches to revolutionize healthcare and medicine. Tara A. Schwetz, Ph.D. is the Assistant Director for Biomedical Science Initiatives in the White House Office of Science and Technology Policy (OSTP). She is currently on detail to OSTP from her role as Associate Deputy Director (ADEPD), National Institutes of Health (NIH). During her tenure as ADEPD, Dr. Schwetz also served as the acting Director of the National Institute of Nursing Research (NINR). Prior to assuming these roles, she was the Chief of the Strategic Planning and Evaluation Branch in the Office of the Director at the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Schwetz led several efforts while at NIAID, including conducting an evaluation of the Centers of Excellence for Influenza Research and Surveillance to facilitate evidence-based decision-making and developing the NIAID Strategic Plan for Tuberculosis Research. Previously, Dr. Schwetz served as the Senior Advisor to the Principal Deputy Director of NIH (DEPD), where she coordinated efforts such as Reimagine HHS, the NIH rigor and reproducibility activities, and the first NIH-Wide Strategic Plan. Dr. Schwetz also served in the dual role of the NIH Environmental influences on Child Health Outcomes (ECHO) Interim Associate Program Director and the Special Assistant to the DEPD. Prior to these roles, she was a Health Science Policy Analyst at the National Institute of Neurological Disorders and Stroke, where she helped develop the National Pain Strategy. Dr. Schwetz started her career at NIH as an AAAS Science and Technology Policy Fellow at NINR. She received a BS in biochemistry with honors from Florida State University and a PhD in biophysics from the University of South Florida, followed by a postdoctoral fellowship at Vanderbilt University.

Read More

Dr. Kim and the delegation for KOSME visit BHI

On September 20th,  BioHealth Innovation, Inc. (BHI) hosted a delegation from KOSME, the Korea SMEs and Startups Agency.  Leading the overseas team was KOSME’s President, Dr. Hakdo Kim, who met with BHI board members, Entrepreneurs in Residence, and recorded a “BioTalk with Rich Bendis” podcast episode in which Dr. Kim discussed a new partnership with BHI and a Memorandum of Understanding KOSME signed with the State of Maryland.

KOSME is a Korean-government funded non-profit created over forty years ago to support small and medium enterprises in Korea.  In 2001, KOSME opened the Northern Virginia-based KBDC as an outpost to support Korean companies interested in joining the US marketplace.   

Read More

Philophos Seeks – Business Development & Relationship Manager

Philophos, Inc. is an innovative Med Tech device company headquartered near Seoul in South Korea.  We develop and manufacture quality, portable and value priced optical coherence tomography (OCT) devices for retina imaging.  We have a functional prototype that is in pilot testing, and we are in the process of securing medical device approval in both Korea and the U.S.  We seek a key management hire who can focus on accelerating sales, marketing and relationship development efforts for the U.S. market.

We are seeking a full-time, Business Development & Relationship Manager to represent Philophos, Inc. in the U.S..  Duties will include identifying, developing, and maintaining vital relationships as the primary role.  Duties will also include supporting a variety of activities associated with launching our operations in the U.S. Our culture is a fast-paced environment that requires the ability to independently support multiple activities and manage deadlines with great coordination and communication skills with our headquarters team. Preferred traits are someone who is organized, adaptable, high-energy, a self-starter and good critical thinker who can overcome challenges.  The candidate must possess excellent presentation skills including both oral and written communication abilities.  

Read More

Maryland wants to ease US entry for South Korean startups – Technical.ly Baltimore

On Monday, Maryland First Lady Yumi Hogan signed a memorandum of understanding with Hakdo Kim, president of the Korea SMEs and Startups Agency (KOSME).

Through this agreement, the two entities will work together to support Korean tech and environmentally focused small and medium-sized businesses, as well as startups, as they enter the American market. That could bring potential for the companies to join the Maryland Department of Commerce’s soft landing program, which connects companies looking to explore the U.S. with offices and resources at local startup spaces.

Image: Officials including Maryland First Lady Yumi Hogan sign an MOU on Sept. 20. (Photo courtesy of Maryland Department of Commerce)

Read More

South Korea cracks world's top 5 innovators while China edges Japan – Nikkei Asia

PARIS/NEW YORK — South Korea has placed among the top five technological innovators for the first time, according to the latest global ranking, as other Asian economic powers moved up the hierarchy.

South Korea jumped from 10th place to fifth in this year's Global Innovation Index, the World Intellectual Property Organization reported Monday. The East Asian country was bested only by Switzerland, Sweden, the U.S. and the U.K.

The WIPO rankings grade 132 economies based on multiple categories. Elsewhere in Asia, Singapore stood in eighth place, unchanged from last year, while China rose two ranks to 12th.

Image: An ice carving robot at a bar in Seoul: South Korea was the highest-ranking Asian country in the World Intellectual Property Organization's Global Innovation Index this year. © Reuters

Read More

DC welcomes the Children’s National Research & Innovation Campus | WTOP

The Children’s National Research & Innovation Campus was officially welcomed to the former Walter Reed Army Medical Center campus on Wednesday with a visit from D.C.’s mayor and city council chair.

The partnership of Children’s National Hospital, Virginia Tech and Johnson & Johnson Innovation – JLABS @ Washington, DC will host biomedical research already underway and support entrepreneurs in early-stage companies that will work to find answers to health problems plaguing children.

Read More

Novavax EVP: It's up to policymakers to decide use of COVID-19 vaccine | Devex

A senior official for American biotech company Novavax said the company is committed to equitable COVID-19 vaccine allocation and has made a “great effort” to manufacture its vaccine in different sites across the globe. However, whether its vaccine will be used as booster shots or prioritized in countries struggling with supply will be up to policymakers, he said.  

Speaking at a Devex event held on the sidelines of the 76th United Nations General Assembly, John Trizzino, executive vice president at Novavax, said policymakers are responsible for determining how the COVID-19 doses will be used.

Read More

George Mason University: Mason Researchers Use Scent Analysis For COVID Diagnostics | Fairfax City, VA Patch

With COVID-19 continuing to spread throughout the world, there is a demand for rapid, noninvasive diagnostics. George Mason University researchers Robin Couch and Allyson Dailey, members of the College of Science and the Institute of Biohealth Innovation, are working to answer that call with their research on volatile organic compounds (VOCs) for infectious disease detection. VOCs are gases that emanate from a variety of sources, including from humans. Much like a sommelier can smell wine and determine the composition of it, Couch and Dailey have been looking at the scent prints of bacteria. They have been able to successfully diagnose mice infected with biothreat agents using this method, and were able to differentiate standard bacteria strains from antibiotic-resistant strains, as seen in Nature Scientific Reports. Mason holds a patent around the technology on the extraction and analysis of gases through the VOC extraction chamber. When the news of COVID struck the world in March 2020, the researchers embraced it as an opportunity to further test their approach on viruses.

Read More

Expand Your Horizons at Frederick’s Premiere Biopharma Lab / Manufacturing Building
  • Multiple Move-in Ready Spec Suites at the end of Q2 2021 
  • Building delivering Q2 2021 
  • Up to 75,000 SF Available Frederick, 
  • Located In Federal Opportunity Zone

Read More

Capital Region Emerges as Undisputed Leader in War on Infectious Diseases · BioBuzz

Since 1900, there have been eight different pandemics that concerned public health across the globe, such as Zika, MERS, Ebola, Swine Flu, and others, which have led to the loss of millions of people and billions of dollars in economic losses. That’s one reason for the establishment of the Global Pandemic Prevention and Biodefense Center in Montgomery County, Maryland. When COVID broke last year, a task force urged for the formation of an organization that could peer past the current crisis and put on its prognostication hat to prepare for future threats. With its long history of thought leadership in infectious diseases and vaccines development, as well as its proximity to federal health and regulatory agencies, the BioHealth Capital Region was the perfect fit for the biodefense center.

Read More

President Biden Announces Members of President’s Council of Advisors on Science and Technology | The White House

WASHINGTON – Today, President Biden announced 30 of America’s most distinguished leaders in science and technology as members of his President’s Council of Advisors on Science and Technology (PCAST). A direct descendant of the scientific advisory committee established by President Eisenhower in 1957 in the weeks after the launch of Sputnik, PCAST is the sole body of external advisors charged with making science, technology, and innovation policy recommendations to the President and the White House.

Read More

Women Building Bio 2021 | VirginiaBio

Join us on September 30th for the 6th year of the Women Building Bio conference. Don’t miss an event where women converge to advance the industry with all stakeholders, men and women, front and center joining forces.

Our half-day hybrid conference will offer full virtual attendance or the option for in-person viewing at one of 5 regional locations across our state. In-person requires pre-registration at a specific location and space is limited, so do not delay!

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright AA(C) BioHealth Innovation 2021
All Rights Reserved.


Spurnus Logo

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio – Supernus Pharmaceuticals

By News Archive

Spurnus Logo

ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for $8.10 per share in cash (or an aggregate of approximately $400 million), payable at closing plus two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (or an aggregate of approximately $50 million), for a total consideration of $9.10 per share in cash (or an aggregate of approximately $450 million). The first CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI® of $150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth $0.50 per share, is payable upon achieving net sales of GOCOVRI of $225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022.

The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, the first and only U.S. Food and Drug Administration (FDA)-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy; and Osmolex ER® (amantadine) extended release tablets, approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.

 

Read More
Cursor and Christine Dingivan of Emmes Washington Business Journal

Christine Dingivan of Emmes – Washington Business Journal

By News Archive

Cursor and Christine Dingivan of Emmes Washington Business Journal

When Christine Dingivan took her first job in biotech, she assumed she would stay a couple years and go back to clinical medicine as a practicing surgeon. But when she discovered how much she loved research, that plan changed permanently.

“It all just came together for me, but it was not the career that I set out for when I went to medical school,” Dingivan says. “When you develop a new drug and it becomes available, whether it’s for cancer or an influenza vaccine or a pandemic — like the Covid-19 vaccines — you see the millions of people that have the opportunity to benefit from that work. You can only treat so many patients in one career, and I really felt like I was making a bigger impact in a way.”

 

Read More
Mimetas Logo

MIMETAS is Hiring!

By News Archive

Mimetas Logo

Will YOU be the next one to join our cause to improve the drug development process utilizing human-relevant tissue and disease models? We are looking for commercial and scientific talent to join our teams in the Netherlands and the USA! We are looking for people to join us in the following roles:

In Gaithersburg, USA:

  • Business Development Manager
  • Westcoast Territory Manager
  • Operations Manager  

In Oegstgeest, NL:

  • Business Development Manager
  • Digital Marketing Specialist
  • Scientific Marketing Writer
  • Product Manager 
  • Field Application Specialist
  • Cell Culture Analyst  

Do you see yourself shining in one of these roles? Apply now and we can’t wait to meet you! See the vacancies here –> https://lnkd.in/gNmZhPQ9

NewImage

Top 10 Quantum Computing Workshop and Conferences to Attend in 2021

By News Archive

NewImage

As you know, quantum computing is a type of computation that harnesses the collective properties of quantum states, such as superposition, interference, and entanglement, to perform calculations. To discuss the future of quantum computing there are some workshops and conferences taking place in 2021 that every person should attend.

Here are the top ten quantum computing workshops and conferences:

Image: https://www.analyticsinsight.net

Read More
Healthcare worker has online conference BVEPR9R 1

Starting a health technology company in Baltimore? Here are 43 resources to know – Technical.ly Baltimore

By News Archive

Healthcare worker has online conference BVEPR9R  1The digital health sector was growing rapidly. Then the pandemic came. In this case, it was a story of growth.

Following distancing requirements and loosening regulations, telemedicine became the name of the game for many healthcare systems across the nation. It was an area where Baltimore startups could add value, whether it was the “digital front door” of b.well Connected Health or Tissue Analytics‘ work with healthcare institutions to remotely monitor woundcare patients.

 

Read More
NewImage

WIB-Capital Region: Build Your Own Biotech Startup Toolkit (BHI’s Sarah Miller to present this Thursday October 14th)

By News Archive

NewImage

Calling all women entrepreneurs! Whether you’re already a founder, thinking of starting your own company, or are curious to learn more about the ins and outs of launching a new venture, join Women In Bio-Capital Region and a panel of women founders to hear their experiences, learn about available resources, and ask any questions you may have. From financing to IP law to business strategy, learn from a diverse group of speakers who will share their experiences and perspectives from the world of biotech start-ups. Join us for a one-stop shop to start building your own personal biotech startup toolkit.

 

Read More
Cursor and JobCreation MarylandLifeSciences Milken pdf

New Opportunities for Job Creation in Maryland’s Life Sciences Industry BY ALISSA DUBETZ, CHARLOTTE KESTEVEN, AND AARON MELAAS

By News Archive

Cursor and JobCreation MarylandLifeSciences Milken pdf

Maryland has one of the nation’s strongest life sciences industries. The state’s array of universities, federal labs, and firms employ 54,000 people, generate breakthrough discoveries, and supply a range of technologies that have been key to the COVID-19 pandemic response. Despite Maryland’s high concentration of employment in research and development (R&D), the sector’s 7.4 percent growth between 2015 and 2020 trailed other leading states such as Massachusetts (58 percent) and North Carolina (38 percent). Beyond R&D employment, the state’s life sciences manufacturing sector expanded at one of the fastest rates nationwide (31 percent), but remains relatively less concentrated than the national average, indicating significant potential for further growth. Maryland’s life sciences industry also faces competition from other states for investment, particularly in entrepreneurs and startup firms that have the potential to sustain job creation across the state.

Read More
TONIX Logo

Tonix Pharmaceuticals Completes Acquisition of Infectious Disease R&D Center in Frederick, MD | citybiz

By News Archive

TONIX Logo

CHATHAM, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced it has completed the acquisition of its new research and development center (RDC) located in Frederick, Md. The approximately 48,000 square foot facility will support Tonix’s expanding infectious disease pipeline, including:

  • TNX-1800 – a live virus vaccine designed to protect against COVID-19 
  • TNX-801 – a live virus vaccine designed to protect against smallpox and monkeypox 
  • TNX-3500 – a small molecule antiviral under development to treat COVID-19 
  • TNX-2100 – a peptide based skin test to measure functional T cell immunity to SARS-CoV-2 

Tonix purchased the RDC from Southern Research, a collaborating partner on TNX-1800 and TNX-801 development.

 

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.